News Releases
-
Promotions & Moves
Alcami Appoints Patrick D. Walsh as Chairman and Chief Executive Officer
He succeeds Walter J. Kaczmarek III, who is stepping down as Chief Executive Officer.Released by: Alcami
-
Humanigen & Emergent Biosolutions Announce Agreement for Phase 3 Covid-19 Therapeutic Candidate
Lenzilumab™ is currently in a Phase 3 clinical trial evaluating patients hospitalized with COVID-19. Humanigen intends to file for EUA first quarter of 2021.Released by: Emergent BioSolutions
-
Vetter continues its successful performance at the 2021 CMO Leadership Awards
Winning five core categories reaffirms Vetter as a trusted solution provider, particularly during globally challenging times.Released by: Vetter Pharma International
-
-
Vetter continues to implement its long-term sustainability strategy
Minister of Transport praises the commitment of the pharmaceutical service provider during global turbulent timesReleased by: Vetter Pharma International
-
Syngene and Deerfield Discovery and Development (3DC) sign 5-year strategic collaboration
...Released by: Syngene
-
CCRM and McMaster Innovation Park (MIP) Partner to Build and Operate Biomanufacturing Campus
...Released by: CCRM
-
-
Syngene International Q2 profit up 64 pc to Rs 128 cr
Press Trust of India | New DelhiReleased by: Syngene
-
Vetter continues its long-term investment strategy to sustain future growth
Existing buildings are repurposed as others continue to be built and recently housedReleased by: Vetter Pharma International
-
Syngene joins global consortium to accelerate research in COVID-19 testing
The consortium brings together a diverse group of companies with synergistic areas of expertiseReleased by: Syngene
-
-
Kohlberg and Mubadala sign a definitive agreement to acquire majority stake in PCI Pharma Services
...Released by: PCI Pharma Services
-
A strong signal in turbulent times: Vetter achieves carbon dioxide-neutral levels
Contract Development and Manufacturing Organization further expands its commitment to climate protectionReleased by: Vetter Pharma International
-
PCI Pharma Services Announces Global Expansion of Clinical Trial Services
PCI Broadens Global Clinical Supply-Chain Service Offerings Into Mainland EuropeReleased by: PCI Pharma Services
-
Mount Sinai Health System, Emergent BioSolutions, and ImmunoTek Bio Centers Form Collaboration
to Develop Emergent’s COVID-19 Hyperimmune Globulin (COVID-HIG) Product Candidate with U.S. Department of Defense FundingReleased by: Emergent BioSolutions
-
Vetter further expands its Development Service with new site in Austria
With the new Vetter Development Service Rankweil site in Austria, Vetter expands its European footprint.Released by: Vetter Pharma International
-
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing
for Johnson & Johnson’s Lead COVID-19 Vaccine CandidateReleased by: Emergent BioSolutions
-
The key to tackling drug development complexity: Collaboration.
Rentschler Biopharma and Vetter team up with joint goal to simplify processes and optimize time-to-marketReleased by: Vetter Pharma International
-
Multimillion Dollar Investment Firmly Establishes Commercial Operations Globally to Support Business
PCI Pharma Services Announces Completion of Biotech Center of Excellence in Philadelphia and Expansions to Biotech Capabilities in EuropeReleased by: PCI Pharma Services
